Consumer Version of Merck & Co’s Famous Manual Is Available

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 10
Volume 6
Issue 10

RAHWAY, NJ-To help serve an increasingly health-conscious public, Merck & Co. has launched its first consumer reference, The Merck Manual of Medical Information-Home Edition.

RAHWAY, NJ—To help serve an increasingly health-conscious public, Merck & Co. has launched its first consumer reference, The Merck Manual of Medical Information—Home Edition.

Based on its physician reference, The Merck Manual of Diagnosis and Therapy, but written in everyday language, the 1,509-page Home Edition provides authoritative, up-to-date information on more than 3,000 medical conditions. The Home Edition has been more than five years in the making, as the more than 200 contributors “translated” the Merck Manual into plain English.

Readers can sample the Home Edition on the Internet at the Merck web site (http://www.merck.com). The Home Edition can be ordered by calling 1-800-999-3633.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content